Placental and fetal consequences of maternal selective serotonin reuptake inhibitor use: current evidence and unresolved questions

母体使用选择性血清素再摄取抑制剂对胎盘和胎儿的影响:现有证据和未解决的问题

阅读:1

Abstract

Serotonin is a neurotransmitter critical for mood regulation, neurodevelopment, and diverse organ functions. It is synthesized from tryptophan through tightly regulated enzymatic pathways that maintain homeostasis, particularly during pregnancy. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed across age groups to manage depression, anxiety, and other mental health conditions, with treatment tailored to individual needs. During pregnancy, SSRIs are widely prescribed or maintained to manage maternal health. Despite decades of research on SSRIs and pregnancy, there continues to be conflicting conclusions with some studies reporting beneficial effects on maternal and fetal health and outcomes, while others suggest potential risks. This review aimed to identify overall trends and evolution of our understanding of SSRI use and pregnancies from studies published from 1983-2025, including comparisons between placental roles of two major model organisms: mice and humans, serotonin biology, pharmacological properties, and prescription mechanisms of SSRIs, and the impact of SSRI use during pregnancy and the continued gaps in current research. Despite extensive research, there is a significant gap in understanding the safety and effects of SSRI use specifically in advanced maternal age pregnancies, as the age of first-time mothers continues to shift past 30 years old, highlighting a critical area for future research and clinical guidance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。